Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member printed answering member label
tabling member	label

Search

1644491

	registered interest
	date	13/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Integrated Care boards
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what is their policy justification for deciding not to define an integrated care board as a “relevant body” in regulation 2 of the National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, with the effect that a range of patient rights formerly imposed on clinical commissioning groups are not now imposed on integrated care boards.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL8440
	answer	answer is ministerial correction date of answer 27/06/2023 answer text <p><del class="ministerial">‘The National Health Service (Integrated Care Boards: Responsibilities) Regulations 2022’</del><ins class="ministerial"> The Health and Care Act 2022 (Consequential and Related Amendments and Transitional Provisions) Regulations 2022 SI/634</ins> has made consequential amendments to regulation 2 of the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, replacing references to Clinical Commissioning Groups with integrated care boards (ICBs). ICBs are now the statutory bodies responsible for patient rights.</p> answering member printed Lord Markham question first answered 27/06/2023 16:18:31 question first ministerially corrected 26/07/2023 13:28:18 answering member 4948 label Biography information for Lord Markham previous answer version 84191 answering member printed Lord Markham answering member 4948 label Biography information for Lord Markham
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1646818

	registered interest
	date	22/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	IVF
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government, further to the Written Answer by Lord Markham on 22 June (HL8340), whether the implantation failure rate for all other treatments is therefore incomparably low relative to that to date for pronuclear transfer; or whether the number of successful treatments to date for pronuclear transfer is incomparably low; and what is the implantation failure rate for all other treatments regulated by the Human Fertilisation and Embryology Authority.
	tabling member printed	Lord Alton of Liverpool
	uin	HL8708
	answer	answer is ministerial correction date of answer 27/06/2023 answer text <p>The Human Fertilisation and Embryology Authority (HFEA) has advised that it has not made any assessment of whether the implantation failure rate for all other treatments is incomparably low relative to that to date for pronuclear transfer; or whether the number of successful treatments to date for pronuclear transfer is incomparably low. The HFEA routinely publish implantation success rates. The implantation failure rate is the remainder.</p><p>The following table shows the average implantation rate and implantation failure rate per embryo transferred from fresh embryo transfer using patients eggs by patient age, 2021.</p><table><tbody><tr><td><p>Year</p></td><td><p>Implantation rate per embryo transferred</p></td><td><p>Implantation failure rate per embryo transferred</p></td></tr><tr><td><p>Age 18 to 34 years old</p></td><td><p>41%</p></td><td><p>59%</p></td></tr><tr><td><p>Age 35 to 37 years old</p></td><td><p>33%</p></td><td><p>67%</p></td></tr><tr><td><p>Age 38 to 39 years old</p></td><td><p>25%</p></td><td><p>75%</p></td></tr><tr><td><p>Age 40 to 42 years old</p></td><td><p>16%</p></td><td><p>84%</p></td></tr><tr><td><p>Age 43 to 50 years old</p></td><td><p>6%</p></td><td><p>94%</p></td></tr></tbody></table><p>Source: HFEA</p><p>Implantation rates for 2021 are preliminary. This data includes IVF treatment cycles begun with the intention of having a live birth only and includes fresh embryo transfers. PGT-A/M/SR treatments and treatments using donor eggs or surrogacy have been excluded.</p> answering member printed Lord Markham question first answered 27/06/2023 16:44:40 answering member 4948 label Biography information for Lord Markham
	tabling member	738 label Biography information for Lord Alton of Liverpool

1646177

	registered interest
	date	20/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Tobacco
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what plans they have to disseminate the guidance published by the Department of Health and Social Care on gov.uk for government engagement with the tobacco industry to all of government, including executive, legislative and judicial branches of government at national and local level, as well as all public authorities.
	tabling member printed	Lord Young of Cookham
	uin	HL8681
	answer	answer is ministerial correction date of answer 27/06/2023 answer text <p>The Department has written to other Government Departments who may engage with the tobacco industry to inform them of the publication of ‘Guidance for government engagement with the tobacco industry’ that was published 19 June 2023. A copy attached. A version of the guidance tailored to local authorities developed in collaboration with the Local Government Association will be published shortly.</p> answering member printed Lord Markham question first answered 27/06/2023 16:13:28 answering member 4948 label Biography information for Lord Markham attachment 1 file name Guidance for government engagement with the tobacco industry - GOV.UK (4).pdf title Attachment
	tabling member	57 label Biography information for Lord Young of Cookham

1646154

	registered interest
	date	20/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diseases
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what practical steps they are taking to embed lessons from the pandemic response to ensure future pandemic preparedness.
	tabling member printed	Lord Mendelsohn
	uin	HL8658
	answer	answer is ministerial correction date of answer 27/06/2023 answer text <p>The United Kingdom has flexible and well-tested pandemic response capabilities. Learning the lessons from COVID-19, we are working with the Centre for Pandemic Preparedness in the UK Health Security Agency to ensure a flexible and capabilities-based approach to pandemic preparedness which will see emergency planners develop and maintain a generic suite of response capabilities across Government. This will enable an approach that can be flexibly deployed to meet the demands of any future pandemic and provide a whole-system response.</p><p>We cannot perfectly predict the characteristics of a new pandemic pathogen and therefore our strategic approach to pandemic preparedness constantly evolves in response to new scientific information, lessons learned from prior pandemics, responses to other infectious disease outbreaks and rigorous exercises to test our response mechanisms.</p><p>Public hearings for Module 1 of the UK COVID-19 Inquiry commenced on 13 June 2023 and will run for six weeks. The Department acknowledges there are valuable lessons to be learnt from COVID-19 to inform our preparedness for future pandemics.</p> answering member printed Lord Markham question first answered 27/06/2023 16:39:09 answering member 4948 label Biography information for Lord Markham
	tabling member	4286 label Biography information for Lord Mendelsohn

1645542

	registered interest
	date	19/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of whether the Voluntary Scheme for Branded Medicines Pricing and Access has caused a reduction in the supply of biosimilar medicines, and any associated impact on (1) patient outcomes, (2) NHS finances in the short term, and (3) the ability to make cost-savings in the longer term.
	tabling member printed	Lord Warner
	uin	HL8633
	answer	answer is ministerial correction date of answer 27/06/2023 answer text <p>The Department recognises the important role that biosimilars and generics play in ensuring affordability, patient access, and supply resilience. We have not seen convincing evidence that the voluntary scheme for branded medicines pricing and access has had an impact on medicines supply including biosimilars, given available mitigations such as provisions in the scheme for companies to apply for price increases should supply of products be otherwise uneconomical.</p> answering member printed Lord Markham question first answered 27/06/2023 16:15:45 answering member 4948 label Biography information for Lord Markham
	tabling member	1732 label Biography information for Lord Warner

1645541

	registered interest
	date	19/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what volume of sales under the Voluntary Scheme for Branded Medicines Pricing and Access are off-patent medicines; and how the suppliers of such medicines are represented in negotiations for the next scheme.
	tabling member printed	Lord Warner
	uin	HL8632
	answer	answer is ministerial correction date of answer 27/06/2023 answer text <p>The information requested is not held centrally. It would not be appropriate for us to comment on a representation of the off-patent sector as this is closely connected with an ongoing legal case.</p> answering member printed Lord Markham question first answered 27/06/2023 16:15:13 answering member 4948 label Biography information for Lord Markham
	tabling member	1732 label Biography information for Lord Warner

1645535

	registered interest
	date	19/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Social Workers: Recruitment
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what steps they are taking to encourage, through organised career structures, more people to enter roles in the care sector.
	tabling member printed	Lord Jones
	uin	HL8602
	answer	answer is ministerial correction date of answer 27/06/2023 answer text <p>We are developing a Care Workforce Pathway, which will set out the knowledge, skills and behaviours needed to work in adult social care, as well as a clear career structure for the workforce. We intend to publish the first part of the pathway, focused on staff in direct care roles, in autumn 2023.</p> answering member printed Lord Markham question first answered 27/06/2023 15:42:19 answering member 4948 label Biography information for Lord Markham
	tabling member	530 label Biography information for Lord Jones

1645500

	registered interest
	date	19/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Social Workers
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government how many people are working in social care roles in England.
	tabling member printed	Lord Jones
	uin	HL8601
	answer	answer is ministerial correction date of answer 27/06/2023 answer text <p>According to Skills for Care, there were 1.5 million people working in adult social care roles in England in 2021/22.</p> answering member printed Lord Markham question first answered 27/06/2023 16:14:57 answering member 4948 label Biography information for Lord Markham
	tabling member	530 label Biography information for Lord Jones

1645389

	registered interest
	date	16/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Neurodiversity: Children
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of current NHS wait times for neurodiversity assessments for children; and what steps they are taking to reduce them.
	tabling member printed	Baroness Hodgson of Abinger
	uin	HL8564
	answer	answer is ministerial correction date of answer 27/06/2023 answer text <p>No specific assessment has been made. NHS England publish quarterly experimental data on how many people, including children, are waiting for an autism assessment. Whilst we recognise that a significant percentage of autism assessments for children are reported through the Community Services Data Set, which is currently not reported on within this publication, the reported data provides useful information to support local areas to assess local demand and adequacy of services.</p><p>Additionally, in a Westminster Hall debate, on 1 February 2023, the Parliamentary Under Secretary of State for Mental Health and Women's Health Strategy at the Department of Health and Social Care committed to look at how we can improve data on attention deficit hyperactivity disorder (ADHD) assessment waiting times, to help improve access to ADHD assessments in a timely way and in line with the National Institute for Health and Care Excellence (NICE) guidelines. On 5 April 2023, NHS England published a national framework and operational guidance for autism assessment services. This guidance, published in an online only format, will help the NHS improve their autism assessment pathways and improve the experience for children and young people referred to an autism assessment service.</p><p>This year, 2023/2024, £4.2 million is available to improve services for autistic children and young people, including autism assessment services and pre- and post-diagnostic support, and the continuation of the Autism in Schools programme. We are committed to increasing investment into mental health services by at least £2.3 billion a year by March 2024 and have set out our aim in the NHS Long Term Plan for an additional 345,000 children and young people to be able to get the mental health support they need.</p> answering member printed Lord Markham question first answered 27/06/2023 11:40:06 answering member 4948 label Biography information for Lord Markham
	tabling member	4301 label Biography information for Baroness Hodgson of Abinger

1644880

	registered interest
	date	14/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of whether any disinvestment decisions have been taken in the UK because of the rebates imposed on companies through the Voluntary Scheme for Branded Medicines Pricing and Access.
	tabling member printed	Lord Clement-Jones
	uin	HL8484
	answer	answer is ministerial correction date of answer 27/06/2023 answer text <p>The Government has considered in broad terms the link between volume-based rebate payments in our medicine pricing schemes and various kinds of investment in our impact assessment of recent updates to the statutory scheme for branded medicines pricing, which operates alongside the voluntary scheme for branded medicines pricing and access (VPAS).</p><p>There are several factors which influence company investment decisions in any particular country or region. Available evidence suggests that supply side factors, such as availability of expert scientific labour and favourable tax conditions are of greatest significance in the decision on future investment. However, we understand that price regulation schemes such as VPAS may be a consideration in the decision to locate some investments, which is why we are committed to agreeing a successor voluntary scheme to VPAS that supports a strong United Kingdom life sciences sector.</p> answering member printed Lord Markham question first answered 27/06/2023 16:14:48 answering member 4948 label Biography information for Lord Markham
	tabling member	3396 label Biography information for Lord Clement-Jones